DOCSLIB.ORG

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development Stefan H.E

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development Stefan H.E TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development Stefan H.E. Kaufmann, Hazel Dockrell, Nick Drager, Mei Mei Ho, Helen Mcshane, Olivier Neyrolles, Tom Ottenhoff, Brij Patel, Danielle Roordink, Francois Spertini, et al. To cite this version: Stefan H.E. Kaufmann, Hazel Dockrell, Nick Drager, Mei Mei Ho, Helen Mcshane, et al.. TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. Frontiers in Immunology, Frontiers, 2017, 8, pp.1203. 10.3389/fimmu.2017.01203. pasteur-02046429 HAL Id: pasteur-02046429 https://hal.archives-ouvertes.fr/pasteur-02046429 Submitted on 22 Feb 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License REVIEW published: 04 October 2017 doi: 10.3389/fimmu.2017.01203 TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development Stefan H. E. Kaufmann1*, Hazel M. Dockrell 2, Nick Drager 3, Mei Mei Ho4, Helen McShane5, Olivier Neyrolles 6, Tom H. M. Ottenhoff 7, Brij Patel 8, Danielle Roordink3, François Spertini 9, Steffen Stenger10, Jelle Thole3, Frank A. W. Verreck11, Ann Williams12 and TBVAC2020 Consortium 1 Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, 2 Immunology and Infection Department, London School of Hygiene and Tropical Medicine, London, United Kingdom, 3 Tuberculosis Vaccine Initiative (TBVI), Lelystad, Netherlands, 4 Bacteriology Division, MHRA-NIBSC, Potters Bar, United Kingdom, 5 University of Oxford, Oxford, United Kingdom, 6 Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France, 7 Leiden University Medical Center, Leiden, Netherlands, 8 RegExcel Consulting Ltd, Surrey, United Kingdom, 9 Centre Hospital Universitaire Vaudois, Lausanne, Switzerland, 10 University Hospital of Ulm, Ulm, Germany, Edited by: 11 Biomedical Primate Research Centre, Rijswijk, Netherlands, 12 Public Health England, London, United Kingdom Kuldeep Dhama, Indian Veterinary Research Institute (IVRI), India TBVAC2020 is a research project supported by the Horizon 2020 program of the Reviewed by: European Commission (EC). It aims at the discovery and development of novel tuber- Adel M. Talaat, University of Wisconsin-Madison, culosis (TB) vaccines from preclinical research projects to early clinical assessment. The United States project builds on previous collaborations from 1998 onwards funded through the EC Shoor Vir Singh, framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners Central Institute for Research on Goats (ICAR), India from outstanding laboratories from all over the world, now totaling 40 institutions. Next Ed C. Lavelle, to the development of novel vaccines, TB biomarker development is also considered Trinity College, Dublin, Ireland an important asset to facilitate rational vaccine selection and development. In addition, *Correspondence: TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, Stefan H. E. Kaufmann [email protected] and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between Specialty section: partners with the common aim of working toward the development of an effective TB This article was submitted to Microbial Immunology, vaccine. Close links with funders and other consortia with shared interests further con- a section of the journal tribute to this goal. Frontiers in Immunology Received: 07 July 2017 Keywords: tuberculosis, bacille Calmette–Guérin, vaccination, biomarker, clinical trial, portfolio management, discovery Accepted: 11 September 2017 Published: 04 October 2017 Citation: Kaufmann SHE, Dockrell HM, INTRODUCTION Drager N, Ho MM, McShane H, Neyrolles O, Ottenhoff THM, Patel B, One hundred years ago, Albert Calmette (1863–1933) and Camille Guérin (1872–1961) had almost Roordink D, Spertini F, Stenger S, reached their goal (1). They had passaged Mycobacterium bovis 200 times at 14 d intervals on potato Thole J, Verreck FAW, Williams A slices soaked with ox gall in their attempt to generate an attenuated vaccine against tuberculosis and TBVAC2020 Consortium (2017) (TB). They had started their program in 1906 and had already obtained preliminary evidence for TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to safety and protection of their candidate in 1913. Yet, they continued until they had completed the Clinical Development. 230th passage before verifying its efficacy and safety in experimental animals including guinea pigs, Front. Immunol. 8:1203. rabbits and non-human primates (NHPs) as well as in the natural host, cattle. The data obtained doi: 10.3389/fimmu.2017.01203 were highly promising so Calmette and Guérin started the first vaccination of a human neonate born Frontiers in Immunology | www.frontiersin.org 1 October 2017 | Volume 8 | Article 1203 Kaufmann et al. TBVAC2020 into a household with a TB patient. Risk of TB in a household- research and development and ensured a well-coordinated and contact infant at those times was extremely high. Yet, the baby efficient TB vaccine research consortium. did not develop TB and after additional encouraging results, At the same time, the pipeline needs to be fed constantly with vaccinations of more than 20,000 neonates in households with new innovative candidates since it is unlikely that one single at least one TB patient were performed between 1921 and 1924. vaccine could protect against all different forms of TB disease in The results of this trial revealed that of the vaccinees 5% had died all age groups and for all indications. Thus, the concept of diver- and 1% of these of TB, whereas knowledge of the time held that a sification gained increasing importance. Different vaccine types quarter of non-vaccinated newborns would die in the first years (subunit vaccines vs. whole cell vaccines), different administra- of life, many of them of TB (1). This is the start of Bacille Bilié tion schedules (pre-exposure vs. post-exposure), different age Calmette-Guérin, later shortened to Bacille Calmette–Guérin groups (neonates vs. adults) and different purposes (prevention (BCG), which remains the only licensed vaccine against TB until of infection vs. disease vs. recurrence of disease), and perhaps today. Although not perfect, this vaccine partially fulfills the even therapeutic TB vaccines have all to be considered. goal set by Calmette and Guérin, since it protects against extra- Already before the beginning of TBVAC2020, it was realized pulmonary forms of disease in infants, including life threatening that an isolated vaccine development approach was inadequate TB meningitis. Unfortunately, in most settings, BCG does not and needed to be complemented by deeper knowledge of patho- reliably prevent pulmonary TB, the most prevalent and the most mechanisms, immunology, and microbiology; by established as contagious form in all age groups from the neonatal to the elderly well as novel animal models; by identifying biosignatures of TB population. The lack of an efficient vaccine against pulmonary disease, risk of disease, vaccine efficacy, and safety (3–6). Finally, TB is a major obstacle to control TB satisfactorily until today. with increasing numbers of vaccines being ready for clinical In 1993, the World Health Organization (WHO) declared TB testing, early clinical trials needed to be integrated. Although a global emergency at a time when some 4–6 million new TB TBVAC2020 and its predecessors respect individual researchers’ cases per year were notified. With the introduction of a new treat- autonomy, it was deemed of increasing importance to also pro- ment regimen, called directly observed treatment, short-course vide a portfolio management process, including consensus gating (DOTS) program, WHO claimed to bring TB under control and criteria, to objectively and transparently guide further product predicted a decline from 6–8 million new cases in 1997 to 2–3 and clinical development of TB vaccine candidates (7). This arti- million new cases by 2017 by implementing highly intensive cle describes the different activities of the Horizon 2020 funded DOTS (2). Unfortunately, this hope failed miserably. The most TBVAC2020 project which is coordinated by TBVI summarizing recent notifications reveal a stunning 10.4 million new cases and recent achievements and future goals as part of the European 1.8 million deaths in 2015. Building on better drug regimens effort to successfully combat TB.Figure 1 provides an overview alone not only proved to be insufficient in controlling TB, it also of the close interactions between different WorkPackage (WP) led to increasing incidences of multi-drug-resistant forms of TB. activities and progression of promising vaccine candidates from At this time, researchers interested in the mechanisms under- discovery via preclinical testing to clinical trial. Although TBVI lying immunopathology
Load more

Recommended publications
  • Advancing Tuberculosis Vaccines from Discovery to Clinical Development
    Research Collection Review Article TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development Author(s): Kaufmann, Stefan H.E.; Dockrell, Hazel M.; Drager, Nick; Ho, Mei M.; McShane, Helen; Neyrolles, Olivier; Ottenhoff, Tom H.M.; Patel, Brij; Roordink, Danielle; Spertini, François; Stenger, Steffen; Thole, Jelle; Verreck, Frank A.W.; Williams, Ann; TBVAC2020 Consortium Publication Date: 2017-10-04 Permanent Link: https://doi.org/10.3929/ethz-b-000197748 Originally published in: Frontiers in Immunology 8, http://doi.org/10.3389/fimmu.2017.01203 Rights / License: Creative Commons Attribution 4.0 International This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library REVIEW published: 04 October 2017 doi: 10.3389/fimmu.2017.01203 TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development Stefan H. E. Kaufmann1*, Hazel M. Dockrell 2, Nick Drager 3, Mei Mei Ho4, Helen McShane5, Olivier Neyrolles 6, Tom H. M. Ottenhoff 7, Brij Patel 8, Danielle Roordink3, François Spertini 9, Steffen Stenger10, Jelle Thole3, Frank A. W. Verreck11, Ann Williams12 and TBVAC2020 Consortium 1 Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, 2 Immunology and Infection Department, London School of Hygiene and Tropical Medicine, London, United Kingdom, 3 Tuberculosis Vaccine Initiative (TBVI), Lelystad, Netherlands, 4 Bacteriology Division, MHRA-NIBSC, Potters Bar, United Kingdom,
    [Show full text]
  • Reassessing Twenty Years of Vaccine Development Against Tuberculosis Edited by : Ulrich E
    REASSESSING TWENTY YEARS OF VACCINE DEVELOPMENT AGAINST TUBERCULOSIS EDITED BY : Ulrich E. Schaible and Stefan H. Kaufmann PUBLISHED IN : Frontiers in Immunology Frontiers Copyright Statement About Frontiers © Copyright 2007-2018 Frontiers Media SA. All rights reserved. Frontiers is more than just an open-access publisher of scholarly articles: it is a pioneering All content included on this site, approach to the world of academia, radically improving the way scholarly research such as text, graphics, logos, button icons, images, video/audio clips, is managed. The grand vision of Frontiers is a world where all people have an equal downloads, data compilations and software, is the property of or is opportunity to seek, share and generate knowledge. Frontiers provides immediate and licensed to Frontiers Media SA permanent online open access to all its publications, but this alone is not enough to (“Frontiers”) or its licensees and/or subcontractors. The copyright in the realize our grand goals. text of individual articles is the property of their respective authors, subject to a license granted to Frontiers. Frontiers Journal Series The compilation of articles constituting The Frontiers Journal Series is a multi-tier and interdisciplinary set of open-access, online this e-book, wherever published, as well as the compilation of all other journals, promising a paradigm shift from the current review, selection and dissemination content on this site, is the exclusive property of Frontiers. For the processes in academic publishing. All Frontiers journals are driven by researchers for conditions for downloading and researchers; therefore, they constitute a service to the scholarly community. At the same copying of e-books from Frontiers’ website, please see the Terms for time, the Frontiers Journal Series operates on a revolutionary invention, the tiered publishing Website Use.
    [Show full text]
  • Optimisation, Harmonisation and Standardisation of the Direct
    Journal of Immunological Methods 469 (2019) 1–10 Contents lists available at ScienceDirect Journal of Immunological Methods journal homepage: www.elsevier.com/locate/jim Research paper Optimisation, harmonisation and standardisation of the direct T mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells ⁎ Rachel Tannera, , Steven G. Smithb,1, Krista E. van Meijgaardenc,1, Federico Giannonid, Morven Wilkiea, Lucia Gabrielee, Carla Palmad, Hazel M. Dockrellb, Tom H.M. Ottenhoffc, Helen McShanea a The Jenner Institute, University of Oxford, UK b Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, UK c Department of Infectious Diseases, Leiden University Medical Centre, Leiden, The Netherlands d Department of Infectious Diseases, Istituto Superiore di Sanità, Italy e Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Italy ARTICLE INFO ABSTRACT Keywords: A major challenge to tuberculosis (TB) vaccine development is the lack of a validated immune correlate of Tuberculosis protection. Mycobacterial growth inhibition assays (MGIAs) represent an unbiased measure of the ability to Vaccine control mycobacterial growth in vitro. A successful MGIA could be applied to preclinical and clinical post-vac- Mycobacterial growth inhibition assay cination samples to aid in the selection of novel vaccine candidates at an early stage and provide a relevant MGIA measure of immunogenicity and protection. However, assay harmonisation is critical to ensure that comparable Harmonisation information can be extracted from different vaccine studies. As part of the FP7 European Research Infrastructures for Poverty Related Diseases (EURIPRED) consortium, we aimed to optimise the direct MGIA, assess repeatability and reproducibility, and harmonise the assay across different laboratories.
    [Show full text]
  • Factors Influencing the Higher Incidence of Tuberculosis Among Migrants and Ethnic Minorities in the UK [Version 2; Peer Review: 2 Approved]
    F1000Research 2018, 7:461 Last updated: 21 AUG 2021 REVIEW Factors influencing the higher incidence of tuberculosis among migrants and ethnic minorities in the UK [version 2; peer review: 2 approved] Sally Hayward 1, Rosalind M. Harding2, Helen McShane3, Rachel Tanner 3 1St John’s College, University of Oxford, Oxford, OX1 3JP, UK 2Department of Zoology, University of Oxford, Oxford, OX2 6GG, UK 3The Jenner Institute, University of Oxford, Oxford, OX1 3PS, UK v2 First published: 13 Apr 2018, 7:461 Open Peer Review https://doi.org/10.12688/f1000research.14476.1 Latest published: 20 Aug 2018, 7:461 https://doi.org/10.12688/f1000research.14476.2 Reviewer Status Invited Reviewers Abstract Migrants and ethnic minorities in the UK have higher rates of 1 2 tuberculosis (TB) compared with the general population. Historically, much of the disparity in incidence between UK-born and migrant version 2 populations has been attributed to differential pathogen exposure, (revision) report due to migration from high-incidence regions and the transnational 20 Aug 2018 connections maintained with TB endemic countries of birth or ethnic origin. However, focusing solely on exposure fails to address the version 1 relatively high rates of progression to active disease observed in some 13 Apr 2018 report report populations of latently infected individuals. A range of factors that disproportionately affect migrants and ethnic minorities, including genetic susceptibility, vitamin D deficiency and co-morbidities such as 1. Jessica L. Potter , Queen Mary University diabetes mellitus and HIV, also increase vulnerability to infection with of London, London, UK Mycobacterium tuberculosis (M.tb) or reactivation of latent infection.
    [Show full text]
  • Replacing, Reducing and Refining the Use of Animals in Tuberculosis
    Review Article Replacing, Reducing and Refining the Use of Animals in Tuberculosis Vaccine Research Rachel Tanner and Helen McShane The Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK Summary Tuberculosis (TB) remains a serious global health threat and an improved vaccine is urgently needed. New candidate TB vaccines are tested using preclinical animal models such as mice, guinea pigs, cattle and non-human primates. Animals are routinely infected with virulent Mycobacterium tuberculosis (Mtb) in challenge experiments to evaluate protective efficacy, raising ethical issues regarding the procedure of infection itself, symptoms of disease and humane end-points. We summarize the importance and limitations of animal models in TB vaccine research and review current alternatives and modifications in the context of the NC3Rs framework for replacing, reducing and refining the use of animals for scientific purposes. Keywords: tuberculosis, vaccine, animal models, Mtb challenge, 3Rs 1 Introduction human-like pulmonary and extrapulmonary lesions observed (Basaraba, 2008; McMurray et al., 1996). Despite the utility of Tuberculosis (TB) is the world’s most deadly infectious disease, small animals in early screens, larger animal models such as with an estimated 9.6 million new cases and 1.5 million deaths cattle and NHPs are considered more relevant to human TB. annually (WHO, 2016). Incidence of infection in endemic coun- NHPs are naturally susceptible to infection with Mtb, and de- tries remains very high despite good coverage with BCG (Ba- velop the most human-like disease with latency and reactivation cillus Calmette-Guérin) vaccine, the only currently available (Flynn et al., 2015). BCG confers some level of protection in vaccine (Mahomed et al., 2006; Moyo et al., 2010).
    [Show full text]
  • MMR Vaccine Attitude and Uptake Research in the United Kingdom: a Critical Review
    Review MMR Vaccine Attitude and Uptake Research in the United Kingdom: A Critical Review Louis Torracinta 1, Rachel Tanner 1,2 and Samantha Vanderslott 3,* 1 Institute of Human Sciences, University of Oxford, Oxford OX2 6QS, UK; [email protected] (L.T.); [email protected] (R.T.) 2 The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK 3 Oxford Vaccine Group, University of Oxford, Oxford OX3 7LE, UK * Correspondence: [email protected] Abstract: This review critically assesses the body of research about Measles-Mumps-and-Rubella (MMR) vaccine attitudes and uptake in the United Kingdom (UK) over the past 10 years. We searched PubMed and Scopus, with terms aimed at capturing relevant literature on attitudes about, and uptake of, the MMR vaccine. Two researchers screened for abstract eligibility and after de- duplication 934 studies were selected. After screening, 40 references were included for full-text review and thematic synthesis by three researchers. We were interested in the methodologies employed and grouped findings by whether studies concerned: (1) Uptake and Demographics; (2) Beliefs and Attitudes; (3) Healthcare Worker Focus; (4) Experimental and Psychometric Intervention; and (5) Mixed Methods. We identified group and individual level determinants for attitudes, operating directly and indirectly, which influence vaccine uptake. We found that access issues, often ignored within the public “anti-vax” debate, remain highly pertinent. Finally, a consistent theme was the effect of misinformation or lack of knowledge and trust in healthcare, often stemming from the Wakefield controversy. Future immunisation campaigns for children, including for COVID-19, should consider Citation: Torracinta, L.; Tanner, R.; both access and attitudinal aspects of vaccination, and incorporate a range of methodologies to assess Vanderslott, S.
    [Show full text]
  • Supplementary Appendix This Appendix Formed Part of the Original Submission and Has Been Peer Reviewed
    Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2020; published online Dec 8. http://dx.doi.org/10.1016/S0140-6736(20)32661-1. Supplementary Information Supplementary Laboratory Methods 2 Table S1 Summary of trials included in the analysis 3 Figure S1 CONSORT participant flow diagram 5 Table S2 Participant disposition for primary analysis in COV002 and COV003 6 Table S3 Participant disposition for secondary analysis in COV002 and COV003 8 Table S4 Baseline characteristics of participants included in the any dose for safety population* 9 Table S5 Timing of vaccine administration in those included in the primary analysis* 11 Figure S2 Kaplan-Meier cumulative incidence of primary symptomatic COVID-19 in LD/SD recipients in the UK, and in SD/SD recipients in the UK and Brazil 12 Figure S3 Kaplan-Meier cumulative incidence of primary symptomatic COVID-19 in SD/SD recipients in the UK, and in SD/SD recipients in the Brazil 13 Table S6 Serious Adverse Events by MedDRA System Organ Class and Preferred Term at any time during the study, in randomised participants who received at least one dose of vaccine 15 Table S7 Adverse Events of Special Interest by Special Interest Category and Preferred Term in randomised participants who received at least one dose of vaccine (Any Dose for Safety Population) 19 Oxford Vaccine Trial Group Authorship 21 Acknowledgements 45 1 Supplementary Laboratory Methods Serum samples were measured at baseline in a validated serological assay using the nucleocapsid antigen of SARS-COV-2 and run at PPD Central Labs (Zaventum, Belgium and Highland Heights, KY, USA).
    [Show full text]
  • Srep43478.Pdf
    www.nature.com/scientificreports OPEN The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays Received: 24 October 2016 Rachel Tanner1, Matthew K. O’Shea1, Andrew D. White2, Julius Müller1, Rachel Harrington- Accepted: 24 January 2017 Kandt1, Magali Matsumiya1, Mike J. Dennis2, Eneida A. Parizotto1, Stephanie Harris1, Published: 03 March 2017 Elena Stylianou1, Vivek Naranbhai1, Paulo Bettencourt1, Hal Drakesmith3, Sally Sharpe2, Helen A. Fletcher4 & Helen McShane1 The current vaccine against tuberculosis, live attenuated Mycobacterium bovis BCG, has variable efficacy, but development of an effective alternative is severely hampered by the lack of an immune correlate of protection. There has been a recent resurgence of interest in functional in vitro mycobacterial growth inhibition assays (MGIAs), which provide a measure of a range of different immune mechanisms and their interactions. We identified a positive correlation between mean corpuscular haemoglobin and in vitro growth of BCG in whole blood from healthy UK human volunteers. Mycobacterial growth in peripheral blood mononuclear cells (PBMC) from both humans and macaques was increased following the experimental addition of haemoglobin (Hb) or ferric iron, and reduced following addition of the iron chelator deferoxamine (DFO). Expression of Hb genes correlated positively with mycobacterial growth in whole blood from UK/Asian adults and, to a lesser extent, in PBMC from South African infants. Taken together our data indicate an association between Hb/iron levels and BCG growth in vitro, which may in part explain differences in findings between whole blood and PBMC MGIAs and should be considered when using such assays. Tuberculosis (TB) remains a serious global health and socioeconomic threat, with 9.6 million new cases and 1.5 million deaths per year1.
    [Show full text]
  • Prot SAP 000.Pdf
    CLINICAL TRIAL PROTOCOL Trial title: Open label, dose escalation and age de-escalation for ChAdOx1 85A in Ugandan adults and adolescents, followed by a Phase IIa randomised, open-label trial among adolescents comparing ChAdOx1 85A prime followed by MVA85A boost versus BCG re- vaccination Short title: EMaBS1 TB Vaccine Study Trial Reference: TB042 UVRI/REC Ref: UNCST Ref: National Drug Authority Ref: LSHTM Ref: OXTREC Ref: 2-18 Date and Version No: 25.08.2017, version 1.1 Chief Investigator: Helen McShane Principal Investigator: Alison Elliott Other Investigators: Anne Wajja, Pontiano Kaleebu Trial Site: Entebbe Hospital and MRC/UVRI Uganda Research Unit on AIDS Sponsor: University of Oxford Funder: Medical Research Council, UK 1 EMABS: Entebbe Mother and Baby Study TB042 Clinical Trial Protocol v1.1 25th August 2017 CONFIDENTIAL Page 1 of 52 Confidentiality Statement This document contains confidential information that must not be disclosed to anyone other than the Sponsor, the Investigator Team, host organisation, and members of the Research Ethics Committees and other regulatory bodies. This information cannot be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Professors Helen McShane and Alison Elliott. Statement of Compliance The trial will be conducted in compliance with the protocol, the International Conference on Harmonisation Good Clinical Practice Guideline E6 (R2) (ICH-GCP), Medicines for Human Use (Clinical Trial) Regulations 2004 (as amended) and
    [Show full text]
  • POSTER PROGRAM Tuesday 20 February 2018
    POSTER PROGRAM Tuesday 20 February 2018 16:15 – 17:45 POSTER DISCUSSION 1: BASIC VACCINE CONCEPTS AND CORRELATES OF PROTECTIVE IMMUNITY Roshanara Facilitators: David Lewinsohn, Oregon Health & Science University (USA) | Vinay Kumar Nandicoori, National Institute of Immunology (India) PD-01 Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) exacerbates TB infection after aerosol challenge in mice – implications for host-directed therapy Rasmus Mortensen, Statens Serum Institute (Denmark) PD-02 Deciphering the role of VapBC TA modules in virulence and pathogenesis of Mycobacterium tuberculosis Sakshi Agarwal, Translational Health Science and Technology Institute (India) PD-03 Mycobacterium tuberculosis hbhA and mtp deletion elicits unique canonical pathways during early infection in THP-1 differentiated macrophages Suventha Moodley, University of KwaZula-Natal (South Africa) PD-04 Targeting ClpB abrogates stress tolerance in Mycobacterium tuberculosis and hence its growth and infectivity Prajna Tripathi, National Institute of Immunology (India) PD-05 Circulating HLA-DR+IFNγhiIL-17hiCD4+T effectors resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis Asma Ahmed, Indian Institute of Science (India) PD-06 PPM, a novel Mycobacterium tuberculosis (Mtb) antigen: a candidate for vaccine development to prevent progression to tuberculosis Chaouki Benabdessalem, Institut Pasteur de Tunis (Tunisia) PD-07 Evaluation of the immunogenicity of a promising vaccine regime to identify immune correlates
    [Show full text]
  • Induction of Specific Antibodies, Igg-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.18.431837; this version posted February 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Induction of specific antibodies, IgG-secreting plasmablasts and memory B cells following BCG vaccination Julia Bitencourt1,2, Morven Wilkie1, Marco Polo Peralta Alvarez1, Ashley Jacobs1,3, Daniel Wright1, Stephanie A. Harris1, Steven G. Smith4,5, Sean Elias1, Andrew White6, Sally Sharpe6, Matthew K. O’Shea1,7, Helen McShane1, Rachel Tanner1*. 1The Jenner Institute, University of Oxford, UK; 2Gonҫalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil; 3University of Cape Town, Cape Town, South Africa; 4London School of Hygiene and Tropical Medicine, UK; 5Division of Biosciences, Brunel University, UK; 6Public Health England, Porton Down, Salisbury, UK; 7Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. *Corresponding author: [email protected] The Jenner Institute, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford, OX3 7DQ. +44(0)1865617615. Abstract Many tuberculosis (TB) vaccine candidates are designed as a boost to BCG; an understanding of the BCG-induced immune response is therefore critical, and the opportunity to relate this to circumstances where BCG does protect may direct the design of more efficacious vaccines. While the T cell response to BCG vaccination has been well-characterised, little is known about the B cell and antibody response.
    [Show full text]
  • A Mycobacterial Growth Inhibition Assay (MGIA) for Bovine TB Vaccine
    Aberystwyth University A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development Pepponi, Ilaria; Khatri, Bhagwati; Tanner, Rachel; Villarreal-Ramos, Bernardo; Vordermeier, Martin; McShane, Helen Published in: Tuberculosis DOI: 10.1016/j.tube.2017.07.008 Publication date: 2017 Citation for published version (APA): Pepponi, I., Khatri, B., Tanner, R., Villarreal-Ramos, B., Vordermeier, M., & McShane, H. (2017). A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development. Tuberculosis, 106, 118-122. https://doi.org/10.1016/j.tube.2017.07.008 Document License CC BY General rights Copyright and moral rights for the publications made accessible in the Aberystwyth Research Portal (the Institutional Repository) are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the Aberystwyth Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the Aberystwyth Research Portal Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. tel: +44 1970 62 2400 email: [email protected] Download date: 01. Oct. 2021 Tuberculosis
    [Show full text]